Neurocrine Biosciences, Inc.
HealthcareNASDAQ:NBIX · NASDAQ Global Select
-$1.89 today
Vol 1.05M · Avg 1.17M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $266.5M |
| Short-term Investments | $1.0B |
| Receivables | $768.1M |
| Inventory | $64.5M |
| Other Current | $287.3M |
| Total Current Assets | $2.4B |
| PP&E (Net) | $538.0M |
| Long-term Investments | $146.1M |
| Tax Assets | $381.4M |
| Other Non-current | $1.4B |
| Total Non-current Assets | $2.5B |
| Total Assets | $4.9B |
Analysis
Selected assets total $4.9B for Latest. The largest visible component is Other Non-current at $1.4B, about 28.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $713.0M +206.0% | $233.0M -7.2% | $251.1M -4.5% | $262.9M -22.9% | $340.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $767.4M -9.0% | $843.1M +8.0% | $780.5M +7.4% | $726.4M +96.1% | $370.5M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $686.8M +43.4% | $479.1M +9.1% | $439.3M +25.5% | $350.0M +88.7% | $185.5M | $533.8M | $399.4M | -$1.7B |
| Inventory | $69.0M +20.2% | $57.4M +49.9% | $38.3M +9.1% | $35.1M +15.1% | $30.5M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $286.5M +155.6% | $112.1M +14.6% | $97.8M +23.6% | $79.1M +73.8% | $45.5M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $2.5B +46.3% | $1.7B +7.3% | $1.6B +10.6% | $1.5B +49.4% | $972.8M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $545.2M -7.9% | $592.0M +70.5% | $347.3M +138.5% | $145.6M -6.5% | $155.8M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 -100.0% | $5.7M | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 -100.0% | $36.5M +2.8% | $35.5M -4.6% | $37.2M | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $1.2B +37.0% | $864.3M +1.8% | $849.4M +111.6% | $401.5M -35.7% | $624.4M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $320.3M -34.1% | $485.7M +33.9% | $362.6M +18.5% | $305.9M -2.9% | $315.1M | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $59.5M +507.1% | $9.8M -80.2% | $49.6M +98.4% | $25.0M +468.2% | $4.4M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $2.1B +5.8% | $2.0B +21.3% | $1.6B +79.7% | $915.2M -16.8% | $1.1B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $4.6B +24.5% | $3.7B +14.4% | $3.3B +37.3% | $2.4B +14.3% | $2.1B | $13.3B | $11.9B | $10.6B |
| Account Payables | $104.9M -4.6% | $110.0M -17.5% | $133.3M +98.1% | $67.3M +30.7% | $51.5M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 -100.0% | $170.1M +0.4% | $169.4M | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 -100.0% | $24.4M +171.1% | $9.0M | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $423.9M +42.4% | $297.7M +13.9% | $261.4M +16.0% | $225.4M +69.1% | $133.3M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $743.4M +46.4% | $507.7M -22.5% | $654.8M +21.8% | $537.7M +118.8% | $245.8M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 -100.0% | $335.1M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $219.7M +32.2% | $166.2M +56.3% | $106.3M +257.9% | $29.7M +141.5% | $12.3M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $635.0M +2.2% | $621.3M +70.4% | $364.6M +195.9% | $123.2M -72.8% | $452.7M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $1.4B +22.1% | $1.1B +10.8% | $1.0B +54.2% | $660.9M -5.4% | $698.5M | $14.7B | $3.7B | $9.6B |
| Common Stock | $100.0K +0.0% | $100.0K +0.0% | $100.0K +0.0% | $100.0K +0.0% | $100.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $447.7M +1433.2% | $29.2M +118.6% | -$157.1M +61.4% | -$406.8M +36.0% | -$635.8M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $13.1M +125.9% | $5.8M -17.1% | $7.0M +188.6% | -$7.9M -364.7% | -$1.7M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $3.3B +25.6% | $2.6B +16.0% | $2.2B +30.7% | $1.7B +24.3% | $1.4B | $9.1B | $7.7B | $3.3B |
| Total Debt | $415.3M -8.7% | $455.1M +6.2% | $428.4M +63.0% | $262.9M -40.3% | $440.4M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$297.7M -234.0% | $222.1M +25.3% | $177.3M | $0 -100.0% | $99.6M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Viatris Inc.
NASDAQ:VTRS
$19.08B
Hologic, Inc.
HOLX
$16.97B
The Cooper Companies, Inc.
NASDAQ:COO
$13.22B
Smith & Nephew plc
NYSE:SNN
$12.98B
Elanco Animal Health Incorporated
NYSE:ELAN
$12.10B
ICON Public Limited Company
NASDAQ:ICLR
$11.17B
Dr. Reddy's Laboratories Limited
NYSE:RDY
$11.11B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.75B
Universal Health Services, Inc.
NYSE:UHS
$9.20B
Tempus AI, Inc.
NASDAQ:TEM
$8.27B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does NBIX have?
Neurocrine Biosciences, Inc. (NBIX) reported $713.00M in cash and equivalents in fiscal 2025.
How much debt does NBIX carry?
Neurocrine Biosciences, Inc. (NBIX) reported $415.30M of total debt, with net debt of -$297,700,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.